Beam Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c)
Director and Officer Trading Arrangements
The following table describes for the quarterly period covered by this report each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name(Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Giuseppe Ciaramella (President) | Adoption(September 26, 2024) | Rule 10b5-1 trading arrangement | Sale | Until September 26, 2025, or such earlier date upon which all transactions are completed or expire without execution. | Up to 35,000 shares(1) |
| Christine Bellon (Chief Legal Officer) | Adoption (September 20, 2024) | Rule 10b5-1 trading arrangement | Until September 20, 2025, or such earlier date upon which all transactions are completed or expire without execution. | Up to 20,000 shares(2) | |
| Bethany Cavanagh (Senior Vice President, Finance) | Adoption (September 18, 2024) | Rule 10b5-1 trading arrangement | Until September 18, 2025, or such earlier date upon which all transactions are completed or expire without execution. | Up to 14,595 shares | |
| Bethany Cavanagh (Senior Vice President, Finance) | Adoption (August 9, 2024) | Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all RSU equity awards that have been or may be granted | Sale | Until final settlement of any covered RSU | Indeterminable(3) |
(1)
Consists of 35,000 shares issuable upon exercise of options to purchase the Company’s common stock pursuant to the Rule 10b-5-1 trading arrangement
(2)
Includes up to 10,000 shares issuable upon exercise of options to purchase the Company’s common stock pursuant to the Rule 10b5-1 trading arrangement.
(3)
The number of shares subject to covered restricted stock units ("RSUs") that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a covered RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.